-- 贝尔金融集团（ASX：BFG）周四向澳大利亚证券交易所提交的文件显示，截至4月30日的四个月内，未经审计的税后净利润（NPAT）为1630万澳元，同比增长197%；营收增长37%至1.096亿澳元。 文件指出，强劲的市场交易和交易活动以及平台业务的持续增长是业绩增长的主要驱动力。在经历了疲软的上半年后，随着2025年下半年交易环境的复苏，业绩显著改善。 文件还补充道，前四个月未经审计的市场收入为7350万澳元，同比增长62%；税后净利润为740万澳元，同比增长423%；平台收入为3320万澳元，同比增长9%；税后净利润为890万澳元，同比增长15%。 该公司股价在最近的周四交易中上涨了6%。
Related Articles
Asia
StarHub's Net Attributable Profit Falls 81% in Q1
StarHub's (SGX:CC3) net attributable profit to shareholders plunged 81% in the first quarter of the year to SG$5.9 million from SG$31.8 million a year earlier, according to a Thursday filing with the Singapore Exchange.Revenue declined 6.1% year over year to SG$507.3 million from SG$540.5 million, mainly due to an across-the-board decline in services revenue.
$SGX:CC3
Asia
Meesho Narrows Consolidated Loss in Fiscal Q4
Meesho (NSE:MEESHO, BOM:544632) narrowed its consolidated attributable loss to 1.66 billion Indian rupees in the fiscal fourth quarter ended March 31, from a loss of 13.9 billion rupees a year ago.Loss per share contracted to 0.36 rupees from a loss per share of 3.39 rupees a year earlier, the online marketplace said in a filing to the Indian stock exchanges on Wednesday. The loss per share was lower than the 0.73 rupees estimated by the analysts polled by Visible Alpha.Revenue from operations in fiscal Q4 increased to 35.3 billion rupees from 24.0 billion rupees a year ago. This is a tad higher than Visible Alpha's estimate of 35.2 billion rupees a year ago.
$BOM:544632$NSE:MEESHO
Asia
Changchun High-Tech Gets Regulatory Nod for Gouty Arthritis Drug
Changchun High-Tech Industry (SHE:000661) subsidiary Changchun Genescience Pharmaceutical obtained China's regulatory approval to manufacture and market its fuxinqibai monoclonal antibody injection.The drug is indicated for acute gouty arthritis attacks in adults poorly responsive to standard therapies, according to a Thursday filing with the Shenzhen bourse.
$SHE:000661